Developer docs
API playgroundTry for free, no card

Search company profiles

Zendal

Full company profile

uuid000dnoe

Namestring
Zendal
Legal namestring
Zendal Health S.A.
Websiteurl
zendal.com
Company typeenum
Private
Founded yearint
1993
Descriptiontext

Zendal Group (legal entity Zendal Health S.A.) is a privately held Spanish biopharmaceutical group headquartered in O Porriño, Pontevedra, operating five GMP-certified production plants across Spain and Portugal and distributing to more than 65 countries. The group is organized as a platform-plus-subsidiary architecture: CZ Vaccines (parent and CDMO franchise), Biofabri (human vaccines, including the Phase 3 MTBVAC tuberculosis candidate), Vetia and Petia (livestock and companion animal health in Spain), Zinereo (pharmaceuticals and probiotics with 80+ years of medicine manufacturing heritage), Probisearch (probiotic R&D services), and the recently integrated Laboratorios Ovejero and Laboratorios Maymó (acquired March 2023). As of 2026 the group employed more than 650 professional staff, reinvests 11%+ of revenue in R&D, and traces its biopharmaceutical track record over 30 years to the 1993 founding of CZ Vaccines within the original Laboratorios Zeltia cluster.

The group's core technology spans proprietary vaccine platforms — Neoleish, the first recombinant DNA vaccine for canine leishmaniasis with over 90% demonstrated effectiveness (launched March 2024); MTBVAC, a live attenuated tuberculosis vaccine in Phase 3 development through Biofabri; and inactivated livestock vaccines including the Bluevac bluetongue range, Colidex for swine colibacilosis, Gudair, the EHD vaccine (EMA-recommended March 2025), and a first trivalent bluetongue vaccine for sheep (European approval April 2026). Revenue is generated through three streams: direct sales of proprietary vaccines and biologics to governments, multinationals, and laboratories via CZ Vaccines, Vetia, and Petia; EU GMP-certified CDMO services for third-party developers from clinical phase I-III through commercial manufacturing; and pharmaceutical and probiotic product sales through the Zinereo and Probisearch brands. Go-to-market is sales-led through direct subsidiaries and government/multi-national tenders, with international distribution via own subsidiaries and partner distributors. Strategic positioning is anchored on the One Health framework (joining the One Health Platform in 2021), and the group was appointed by the EU in 2023 alongside Reig Jofre to guarantee European vaccine production capacity for future health emergencies.

Short descriptiontext

Zendal is a privately held Spanish biopharmaceutical group operating five GMP-certified production plants in Spain and Portugal. It develops, manufactures, and commercializes vaccines, biologicals, probiotics, and pharmaceutical products across human and animal health, serving governments, multinationals, and laboratories in 65+ countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersPontevedra, Spain
HQ citystring
Pontevedra
HQ countrystring
Spain
HQ regionstring
Europe
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
human and animal vaccines, biological products, biopharmaceutical manufacturing, CDMO services, veterinary pharmaceuticals
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceuticals (Vaccines & Biological Products)
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Vaccine and Biological Product Manufacturing
TypeOne Time License
Description

Research, development, manufacturing and commercialization of biologics, vaccines, pharmaceuticals and probiotics for human and animal health. CZ Vaccines serves as the main European actor in biotechnological development and manufacturing, producing for laboratories, multinationals and governments globally.

zendal.com
2CDMO Services
TypeManaged Services
Description

Contract Development and Manufacturing Organization services offered to third-party companies with EU GMP certification, providing development through clinical phase I-III and commercial manufacturing capabilities

zendal.com
3Pharmaceutical Products
TypeOne Time License
Description

Production and sale of pharmaceutical medicines and probiotics of pharmaceutical quality through Zinereo brand, with over 80 years of experience in development and manufacture of medicines

Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 6 records shown
1Neoleish
Description

First recombinant DNA vaccine for canine leishmaniasis, demonstrating over 90% effectiveness against canine leishmaniasis.

+5 more records
Core offering1 text field

Zendal is a vertically integrated biopharmaceutical group that researches, develops, manufactures, and commercializes vaccines, biological products, probiotics, and pharmaceutical products for human and animal healthcare. Its portfolio spans proprietary vaccines (Neoleish, MTBVAC, Bluevac, Colidex, EHD, trivalent bluetongue) plus CDMO services offered through EU GMP-certified facilities to third-party laboratories, multinationals, and governments across 65+ countries.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Neoleish vaccine demonstrated over 90% effectiveness against canine leishmaniasis
+2 more records
Product overview1 text field

Zendal Group is a biopharmaceutical conglomerate operating a platform-plus-subsidiary architecture, comprising eight companies focused on research, development, manufacturing, and marketing of biologicals, vaccines, probiotics, and pharmaceutical products for human and animal healthcare. The portfolio is organized across specialized subsidiaries: CZ Vaccines serves as the parent company and primary CDMO services provider with EU GMP certification; Biofabri handles human vaccines including the Phase 3 MTBVAC tuberculosis vaccine; Vetia and Petia address livestock and companion animal health respectively; Zinereo and Probisearch focus on probiotics; Laboratorios Ovejero and Maymó (acquired 2023) round out the group. Key products include Neoleish (first recombinant DNA vaccine for canine leishmaniasis), Bluevac and Gudair (livestock vaccines), trivalent bluetongue vaccine, and the EHD vaccine. The group operates five production plants across Spain and Portugal, maintains R&D centers in multiple locations, and distributes to over 65 countries.

Product and service7 records
1Neoleish Recombinant DNA Vaccine
CategoryCompanion Animal Vaccine
Description

First recombinant DNA vaccine for canine leishmaniasis, demonstrating over 90% effectiveness. Developed in partnership with the Spanish National Research Council (CSIC). Targets canine leishmaniasis prevention in companion animals (dogs), distributed to veterinary professionals.

2Bluevac Bluetongue Vaccine
CategoryLivestock Vaccine
Description

Range of inactivated vaccines to combat bluetongue disease in bovine cattle and sheep. Part of Vetia's livestock vaccine portfolio distributed in Europe.

3Trivalent Bluetongue Vaccine (serotypes 1, 4 and 8)
CategoryLivestock Vaccine
Description

First trivalent bluetongue vaccine for sheep covering serotypes 1, 4 and 8. Received European approval in April 2026. Target segment: ovine livestock.

4Epizootic Haemorrhagic Disease (EHD) Vaccine
CategoryLivestock Vaccine
Description

First vaccine against Epizootic Haemorrhagic Disease (EHD) launched in Spain. EMA recommendation received March 2025. Used for livestock disease prevention.

5Gudair Vaccine
CategoryLivestock Vaccine
Description

Vaccine product in the Zendal animal health portfolio, listed as a distinctive offering alongside Bluevac and Neoleish. Used for livestock disease prevention.

6Colidex Swine Colibacilosis Vaccine
CategoryLivestock Vaccine
Description

Vaccine against swine colibacilosis, part of Vetia's range of biological products for swine animals. Targets livestock producers and the swine farming industry.

7CDMO Services (Contract Development and Manufacturing)
CategoryContract Manufacturing Services
Description

Contract Development and Manufacturing Organization services offered to third-party companies with EU GMP certification, providing development through clinical phase I-III and commercial manufacturing capabilities. CZ Vaccines serves as the main European CDMO actor in biotechnological development and manufacturing, producing for laboratories, multinationals and governments globally.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
1IMAGINE Clinical Trial Partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-02-01
Description

Biofabri and IAVI announced first vaccinations in IMAGINE clinical trial - a large-scale safety and efficacy trial of tuberculosis vaccine candidate MTBVAC.

zendal.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-06-01
Description

TBVI (TuBercculosis Vaccine Initiative) signed contract with European Health and Digital Executive Agency to accelerate final development of MTBVAC tuberculosis vaccine candidate.

3Spanish National Research Council (CSIC)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-03-01
Description

Partnership for development of Neoleish recombinant DNA vaccine - the first recombinant DNA vaccine for canine leishmaniasis, demonstrating over 90% effectiveness. CSIC collaboration provided the scientific foundation for this innovative vaccine technology.

openpr.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-07-01
Description

Joint appointment by EU to ensure vaccine production capacity in Europe in case of future health emergencies, combining Zendal's manufacturing expertise with Reig Jofre's capabilities.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-03-01
Description

Partnership for development, manufacturing and distribution of MTBVAC novel tuberculosis vaccine. BIOFABRI and Bharat Biotech partnered to make the TB vaccine available globally.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-07-01
Description

Partnership to advance tuberculosis vaccine candidate MTBVAC into efficacy trials. IAVI and Zendal announced expanded agreement in 2023 to partner on development of MTBVAC, with IAVI receiving funding for efficacy trial in Africa.

Strategic tierMinorTypeOthersAnnounced on2021-01-01
Description

Joined the One Health Platform at end of 2021 - a network at state level combining efforts of over 100 organisations with interdisciplinary and cross-sectional nature promoting integrated health approaches.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Valneva
TypeDirect peer
Description

European specialty vaccine company combining proprietary vaccine development with CDMO services. Mirrors Zendal's hybrid proprietary-vaccine + biologics-CDMO model and shares a similar scale and European footprint.

TypeDirect peer
Description

Specialty vaccine developer and CDMO with proprietary late-stage vaccine assets. Comparable to Zendal on the biologics-CDMO plus proprietary-vaccine business mix (Biofabri/CZ Vaccines) and clinical-stage execution model.

3Sanofi Pasteur
TypeBroad incumbent
Description

Sanofi's vaccine franchise, one of the world's largest human-vaccine manufacturers. Provides a benchmark for Biofabri's MTBVAC aspirations in terms of scale, regulatory muscle, and global public-health tenders.

TypeDirect peer
Description

Indian vaccine developer partnered with Zendal/BioFabri on MTBVAC. Comparable across innovative human-vaccine development, recombinant platforms, and global distribution via licensing partnerships.

TypeBroad incumbent
Description

Animal-health division of Merck/MSD with a global livestock and companion-animal vaccine franchise. Comparable at the portfolio level to Zendal's Vetia, especially in ruminant and swine vaccine categories.

TypeDirect peer
Description

Spanish animal-health and human-vaccine manufacturer headquartered in Girona. Directly comparable to Zendal's Vetia, Petia, and Biofabri businesses across livestock, companion-animal, and human vaccines within the same Iberian ecosystem.

TypeDirect peer
Description

German CDMO focused on vaccines and biologics with EU GMP manufacturing capacity. Directly comparable to CZ Vaccines' biologics-CDMO proposition and EU strategic-manufacturing positioning.

TypeBroad incumbent
Description

Largest global animal-health company with a comprehensive vaccine portfolio for livestock and companion animals. Provides the upper-end scale benchmark for Zendal's Vetia and Petia franchises.

TypeBroad incumbent
Description

Global vaccine leader across pediatric, travel, and endemic-disease segments. Comparable to Zendal's biologics manufacturing and CDMO ambitions, particularly in mass-vaccination public-health contracts.

10Boehringer Ingelheim Animal Health
TypeBroad incumbent
Description

Animal-health division of Boehringer Ingelheim covering livestock and companion-animal vaccines and pharmaceuticals. Broad incumbent whose veterinary vaccine portfolio overlaps with Zendal's Vetia products.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Subsidiaries8 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Zendal

Biopharmaceuticals (Vaccines & Biological Products)zendal.com

Zendal is a privately held Spanish biopharmaceutical group operating five GMP-certified production plants in Spain and Portugal. It develops, manufactures, and commercializes vaccines, biologicals, probiotics, and pharmaceutical products across human and animal health, serving governments, multinationals, and laboratories in 65+ countries.

What Zendal does

Zendal Group (legal entity Zendal Health S.A.) is a privately held Spanish biopharmaceutical group headquartered in O Porriño, Pontevedra, operating five GMP-certified production plants across Spain and Portugal and distributing to more than 65 countries. The group is organized as a platform-plus-subsidiary architecture: CZ Vaccines (parent and CDMO franchise), Biofabri (human vaccines, including the Phase 3 MTBVAC tuberculosis candidate), Vetia and Petia (livestock and companion animal health in Spain), Zinereo (pharmaceuticals and probiotics with 80+ years of medicine manufacturing heritage), Probisearch (probiotic R&D services), and the recently integrated Laboratorios Ovejero and Laboratorios Maymó (acquired March 2023). As of 2026 the group employed more than 650 professional staff, reinvests 11%+ of revenue in R&D, and traces its biopharmaceutical track record over 30 years to the 1993 founding of CZ Vaccines within the original Laboratorios Zeltia cluster.

The group's core technology spans proprietary vaccine platforms — Neoleish, the first recombinant DNA vaccine for canine leishmaniasis with over 90% demonstrated effectiveness (launched March 2024); MTBVAC, a live attenuated tuberculosis vaccine in Phase 3 development through Biofabri; and inactivated livestock vaccines including the Bluevac bluetongue range, Colidex for swine colibacilosis, Gudair, the EHD vaccine (EMA-recommended March 2025), and a first trivalent bluetongue vaccine for sheep (European approval April 2026). Revenue is generated through three streams: direct sales of proprietary vaccines and biologics to governments, multinationals, and laboratories via CZ Vaccines, Vetia, and Petia; EU GMP-certified CDMO services for third-party developers from clinical phase I-III through commercial manufacturing; and pharmaceutical and probiotic product sales through the Zinereo and Probisearch brands. Go-to-market is sales-led through direct subsidiaries and government/multi-national tenders, with international distribution via own subsidiaries and partner distributors. Strategic positioning is anchored on the One Health framework (joining the One Health Platform in 2021), and the group was appointed by the EU in 2023 alongside Reig Jofre to guarantee European vaccine production capacity for future health emergencies.

Zendal firmographics

Firmographics
Name
Zendal
Legal name
Zendal Health S.A.
Website
https://zendal.com
Company type
Private
Founded year
1993
Operating status
Operating
Headcount range
251–500 employees
Short description
Zendal is a privately held Spanish biopharmaceutical group operating five GMP-certified production plants in Spain and Portugal. It develops, manufactures, and commercializes vaccines, biologicals, probiotics, and pharmaceutical products across human and animal health, serving governments, multinationals, and laboratories in 65+ countries.
Ownership category
akta.pro rank

Where Zendal is headquartered

Location

Headquarters

HQ city
Pontevedra
HQ country
Spain
HQ region
Europe

Offices5 records

Markets served

Zendal business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

  1. Vaccine and Biological Product Manufacturing: Research, development, manufacturing and commercialization of biologics, vaccines, pharmaceuticals and probiotics for human and animal health. CZ Vaccines serves as the main European actor in biotechnological development and manufacturing, producing for laboratories, multinationals and governments globally.
  2. CDMO Services: Contract Development and Manufacturing Organization services offered to third-party companies with EU GMP certification, providing development through clinical phase I-III and commercial manufacturing capabilities
  3. Pharmaceutical Products: Production and sale of pharmaceutical medicines and probiotics of pharmaceutical quality through Zinereo brand, with over 80 years of experience in development and manufacture of medicines

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Zendal product offering

Product offering

Core offering

Zendal is a vertically integrated biopharmaceutical group that researches, develops, manufactures, and commercializes vaccines, biological products, probiotics, and pharmaceutical products for human and animal healthcare. Its portfolio spans proprietary vaccines (Neoleish, MTBVAC, Bluevac, Colidex, EHD, trivalent bluetongue) plus CDMO services offered through EU GMP-certified facilities to third-party laboratories, multinationals, and governments across 65+ countries.

Product overview

Zendal Group is a biopharmaceutical conglomerate operating a platform-plus-subsidiary architecture, comprising eight companies focused on research, development, manufacturing, and marketing of biologicals, vaccines, probiotics, and pharmaceutical products for human and animal healthcare. The portfolio is organized across specialized subsidiaries: CZ Vaccines serves as the parent company and primary CDMO services provider with EU GMP certification; Biofabri handles human vaccines including the Phase 3 MTBVAC tuberculosis vaccine; Vetia and Petia address livestock and companion animal health respectively; Zinereo and Probisearch focus on probiotics; Laboratorios Ovejero and Maymó (acquired 2023) round out the group. Key products include Neoleish (first recombinant DNA vaccine for canine leishmaniasis), Bluevac and Gudair (livestock vaccines), trivalent bluetongue vaccine, and the EHD vaccine. The group operates five production plants across Spain and Portugal, maintains R&D centers in multiple locations, and distributes to over 65 countries.

Differentiator

Problem solved

Functional benefit

Brands

  • Neoleish: First recombinant DNA vaccine for canine leishmaniasis, demonstrating over 90% effectiveness against canine leishmaniasis.
  • MTBVAC
  • Bluevac
  • Gudair
  • Colidex
  • Llovet

Products and services

  • Neoleish Recombinant DNA Vaccine First recombinant DNA vaccine for canine leishmaniasis, demonstrating over 90% effectiveness. Developed in partnership with the Spanish National Research Council (CSIC). Targets canine leishmaniasis prevention in companion animals (dogs), distributed to veterinary professionals.
  • Bluevac Bluetongue Vaccine Range of inactivated vaccines to combat bluetongue disease in bovine cattle and sheep. Part of Vetia's livestock vaccine portfolio distributed in Europe.
  • Trivalent Bluetongue Vaccine (serotypes 1, 4 and 8) First trivalent bluetongue vaccine for sheep covering serotypes 1, 4 and 8. Received European approval in April 2026. Target segment: ovine livestock.
  • Epizootic Haemorrhagic Disease (EHD) Vaccine First vaccine against Epizootic Haemorrhagic Disease (EHD) launched in Spain. EMA recommendation received March 2025. Used for livestock disease prevention.
  • Gudair Vaccine Vaccine product in the Zendal animal health portfolio, listed as a distinctive offering alongside Bluevac and Neoleish. Used for livestock disease prevention.
  • Colidex Swine Colibacilosis Vaccine Vaccine against swine colibacilosis, part of Vetia's range of biological products for swine animals. Targets livestock producers and the swine farming industry.
  • CDMO Services (Contract Development and Manufacturing) Contract Development and Manufacturing Organization services offered to third-party companies with EU GMP certification, providing development through clinical phase I-III and commercial manufacturing capabilities. CZ Vaccines serves as the main European CDMO actor in biotechnological development and manufacturing, producing for laboratories, multinationals and governments globally.

Quantifiable outcome

  • Neoleish vaccine demonstrated over 90% effectiveness against canine leishmaniasis
  • +2 more outcomes

Companies that use Zendal

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Zendal technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Zendal partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • IMAGINE Clinical Trial PartnerscoreStrategic or Co-development Partner · 1 February 2025Biofabri and IAVI announced first vaccinations in IMAGINE clinical trial - a large-scale safety and efficacy trial of tuberculosis vaccine candidate MTBVAC.
  • TBVIcoreStrategic or Co-development Partner · 1 June 2024TBVI (TuBercculosis Vaccine Initiative) signed contract with European Health and Digital Executive Agency to accelerate final development of MTBVAC tuberculosis vaccine candidate.
  • Spanish National Research Council (CSIC)coreStrategic or Co-development Partner · 1 March 2024Partnership for development of Neoleish recombinant DNA vaccine - the first recombinant DNA vaccine for canine leishmaniasis, demonstrating over 90% effectiveness. CSIC collaboration provided the scientific foundation for this innovative vaccine technology.
  • Reig JofrecoreStrategic or Co-development Partner · 1 July 2023Joint appointment by EU to ensure vaccine production capacity in Europe in case of future health emergencies, combining Zendal's manufacturing expertise with Reig Jofre's capabilities.
  • Bharat BiotechcoreStrategic or Co-development Partner · 1 March 2022Partnership for development, manufacturing and distribution of MTBVAC novel tuberculosis vaccine. BIOFABRI and Bharat Biotech partnered to make the TB vaccine available globally.
  • IAVIcoreStrategic or Co-development Partner · 1 July 2021Partnership to advance tuberculosis vaccine candidate MTBVAC into efficacy trials. IAVI and Zendal announced expanded agreement in 2023 to partner on development of MTBVAC, with IAVI receiving funding for efficacy trial in Africa.
  • One Health PlatformminorOthers · 1 January 2021Joined the One Health Platform at end of 2021 - a network at state level combining efforts of over 100 organisations with interdisciplinary and cross-sectional nature promoting integrated health approaches.

Scale indicators8 records

Recent moves9 records

Expansion highlights6 records

Zendal competitors and assessment

Company assessment

Direct peers

  • Valneva: European specialty vaccine company combining proprietary vaccine development with CDMO services. Mirrors Zendal's hybrid proprietary-vaccine + biologics-CDMO model and shares a similar scale and European footprint.
  • Bavarian Nordic: Specialty vaccine developer and CDMO with proprietary late-stage vaccine assets. Comparable to Zendal on the biologics-CDMO plus proprietary-vaccine business mix (Biofabri/CZ Vaccines) and clinical-stage execution model.
  • Bharat Biotech: Indian vaccine developer partnered with Zendal/BioFabri on MTBVAC. Comparable across innovative human-vaccine development, recombinant platforms, and global distribution via licensing partnerships.
  • HIPRA: Spanish animal-health and human-vaccine manufacturer headquartered in Girona. Directly comparable to Zendal's Vetia, Petia, and Biofabri businesses across livestock, companion-animal, and human vaccines within the same Iberian ecosystem.
  • IDT Biologika: German CDMO focused on vaccines and biologics with EU GMP manufacturing capacity. Directly comparable to CZ Vaccines' biologics-CDMO proposition and EU strategic-manufacturing positioning.

Broad incumbents

  • Sanofi Pasteur: Sanofi's vaccine franchise, one of the world's largest human-vaccine manufacturers. Provides a benchmark for Biofabri's MTBVAC aspirations in terms of scale, regulatory muscle, and global public-health tenders.
  • Merck Animal Health (MSD AH): Animal-health division of Merck/MSD with a global livestock and companion-animal vaccine franchise. Comparable at the portfolio level to Zendal's Vetia, especially in ruminant and swine vaccine categories.
  • Zoetis: Largest global animal-health company with a comprehensive vaccine portfolio for livestock and companion animals. Provides the upper-end scale benchmark for Zendal's Vetia and Petia franchises.
  • GSK Vaccines: Global vaccine leader across pediatric, travel, and endemic-disease segments. Comparable to Zendal's biologics manufacturing and CDMO ambitions, particularly in mass-vaccination public-health contracts.
  • Boehringer Ingelheim Animal Health: Animal-health division of Boehringer Ingelheim covering livestock and companion-animal vaccines and pharmaceuticals. Broad incumbent whose veterinary vaccine portfolio overlaps with Zendal's Vetia products.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Zendal social profiles

Digital presence

Zendal compliance and trust

Trust signal

Compliance2 records

Zendal financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Zendal leadership team

Management profile

Number of profiles

Zendal subsidiaries and ownership

Company hierarchy

Subsidiaries8 records

Zendal funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Zendal M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Zendal

What does Zendal do?

Zendal is a vertically integrated biopharmaceutical group that researches, develops, manufactures, and commercializes vaccines, biological products, probiotics, and pharmaceutical products for human and animal healthcare. Its portfolio spans proprietary vaccines (Neoleish, MTBVAC, Bluevac, Colidex, EHD, trivalent bluetongue) plus CDMO services offered through EU GMP-certified facilities to third-party laboratories, multinationals, and governments across 65+ countries.

Is Zendal a public or private company?

Zendal is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Zendal founded?

Zendal was founded in 1993. It employs 251 to 500 people.

Where is Zendal based?

Zendal is headquartered in Pontevedra, Spain, in the Europe region.

How does Zendal make money?

Three revenue lines are on record. Vaccine and Biological Product Manufacturing is the primary driver. The others are CDMO Services and pharmaceutical Products.

Who are Zendal's main competitors?

Direct peers on record are Valneva, Bavarian Nordic, Bharat Biotech, HIPRA and IDT Biologika. Broad incumbents are Sanofi Pasteur, Merck Animal Health (MSD AH), Zoetis, GSK Vaccines and Boehringer Ingelheim Animal Health.

Does Zendal have an API?

No public API is recorded for Zendal.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireCompanion Animal Veterinary Vaccines Research Report 2026: $5.38 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035FThe companion animal veterinary vaccines market is projected to grow from $4.19 billion in 2026 to $5.38 billion by 2030, driven by pet humanization trends and increased pet healthcare expenditure. Notable developments include Mars Inc.'s acquisition of Heska Corp. for approximately $1.3 billion in June 2023 and Zendal Group's Neoleish recombinant DNA vaccine launched in 2024, which demonstrated over 90% effectiveness against canine leishmaniasis. North America leads the market, followed by Asia-Pacific, while U.S. pet services spending rose 8.5% from 2022 to 2025.openPR.comEmerging Growth Patterns Driving Expansion in the Companion Animal Veterinary Vaccines MarketThe companion animal veterinary vaccines market is projected to grow to $5.38 billion by 2030, with a compound annual growth rate of 6.5%, driven by pet humanization trends, increased pet healthcare spending, and advances in vaccine technology. A notable transaction in the sector was Mars Inc.'s acquisition of Heska Corp. for $1.3 billion in June 2023, integrating Heska's diagnostics and vaccine capabilities into Mars Petcare's operations. In March 2024, Spain-based Zendal Group launched Neoleish, the first recombinant DNA vaccine for canine leishmaniasis, developed in partnership with the Spanish National Research Council, demonstrating over 90% effectiveness.